Artiva Biotherapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Artiva Biotherapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	$251000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$89.81M	-$67.28M
Operating income as a percentage of revenue.	–	-26805.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$83.86M	-$65.37M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-5.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-5.00

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$26.70M	$40.23M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$130.94M	$209.58M
Everything the company owes — debt, unpaid bills, and other obligations.	$20.97M	$22.94M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$109.97M	$186.64M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$76.80M	-$55.00M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.59M	$642000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$79.39M	-$55.64M